Search research articles

关于 JoVE

概览领导团队博客 JoVE 帮助中心

作者

出版流程编辑委员会范围与政策同行评审常见问题投稿

图书馆员

用户评价订阅访问资源图书馆顾问委员会常见问题

研究

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments 存档

教育

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual 教师资源中心教师网站

使用条款与条件

相关概念视频

Peptic Ulcer Disease IV: Management

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序

Same author

Efficacy and Safety of Rituximab in Pemphigus Foliaceus: A Systematic Review and Meta-analysis.

Dermatology and therapy·2026

Same author

Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS).

European journal of cancer (Oxford, England : 1990)·2026

Same author

Comment on 'Incidence and Mortality of Mucous Membrane Pemphigoid in France': reply from authors.

The British journal of dermatology·2026

Same author

Predicting Age-Related Facial Hyperpigmentation via Dermatologist Knowledge Elicitation and Generative Modeling.

Dermatology and therapy·2026

Same author

PD-1 and TIGIT coexpression enables selective enrichment of clonally expanded tumor-reactive CD8 T cells for melanoma TIL therapy.

Journal of translational medicine·2026

Same author

Daratumumab as a therapeutic option for rituximab-recalcitrant pemphigus.

The Journal of investigative dermatology·2026

Search research articles

相关实验视频

Updated: May 29, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

使用利图西马布和短期复发预测器优化囊管管理.

Vivien Hébert¹, Sami Hamwi¹, Emmanuelle Tancrède-Bohin²

¹Department of Dermatology, Centre Hospitalier Universitaire de Rouen and Institut National de la Santé et de la Recherche Médicale (INSERM) U1234, Normandie University, Rouen, France.

JAMA dermatology

|February 5, 2025

概括

在6个月后进行额外的Rituximab输液可以降低复发的预测因素的患者的尾虫复发率. 这种先发制人的治疗策略表明,它有望保持完全缓解并尽量减少皮质类固醇的使用.

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

相关实验视频

Last Updated: May 29, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

科学领域:

皮肤病学皮肤病学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

利图西马布已被批准用于中度至重度的.
显著的百分比的患者在一年内复发标准的Rituximab治疗.

研究的目的:

为了评估额外的Rituximab输液在6个月后的疗效,在获得完全缓解 (CR) 但表现出复发预测因素的虫患者中.
评估对CR率,复发率和安全性的影响.

主要方法:

一项多中心队列研究,涉及87名新诊断的尾虫患者,接受RITUX 3疗法治疗.
在6个月的CR中,患有复发预测因素 (高PDAI,抗DSG1/DSG3抗体升高) 的患者接受了额外的Rituximab输液.
测量结果包括12个月后没有皮质类固醇的CR,复发率和安全性.

主要成果:

在77名在6个月的CR患者中,由于复发预测因素,30人接受了额外的Rituximab输液.
整体复发率为2.6%,只有2名患者复发.
在12个月后,93.5%的患者在6个月后达到CR,在不使用皮质类固醇的情况下保持CR.

结论:

以复发预测因子 (PDAI,抗DSG1/DSG3抗体) 为指导的预防性rituximab治疗可以显著降低pemphigus患者的短期复发率.
这一策略可以改善长期的疾病控制,并减少对皮质类固醇的需要.